about
Human osteoclast-poor osteopetrosis with hypogammaglobulinemia due to TNFRSF11A (RANK) mutationsHot spots of retroviral integration in human CD34+ hematopoietic cellsHomeostatic expansion of autoreactive immunoglobulin-secreting cells in the Rag2 mouse model of Omenn syndromeGut-tropic T cells that express integrin α4β7 and CCR9 are required for induction of oral immune tolerance in mice.Insertion sites in engrafted cells cluster within a limited repertoire of genomic areas after gammaretroviral vector gene therapyRANK-dependent autosomal recessive osteopetrosis: characterization of five new cases with novel mutationsIntestinal microbiota sustains inflammation and autoimmunity induced by hypomorphic RAG defects.Lentiviral-mediated gene therapy restores B cell tolerance in Wiskott-Aldrich syndrome patients.Correction of murine Rag2 severe combined immunodeficiency by lentiviral gene therapy using a codon-optimized RAG2 therapeutic transgene.Vitamin A and immune regulation: role of retinoic acid in gut-associated dendritic cell education, immune protection and tolerance.Hypomorphic mutation in the RAG2 gene affects dendritic cell distribution and migration.Anti-CD3ε mAb improves thymic architecture and prevents autoimmune manifestations in a mouse model of Omenn syndrome: therapeutic implications.Integration of retroviral vectors induces minor changes in the transcriptional activity of T cells from ADA-SCID patients treated with gene therapy.IL-10 critically modulates B cell responsiveness in Rankl-/- mice.Recombination-activating gene 1 (Rag1)-deficient mice with severe combined immunodeficiency treated with lentiviral gene therapy demonstrate autoimmune Omenn-like syndrome.β7 integrins are required to give rise to intestinal mononuclear phagocytes with tolerogenic potential.Reply: To PMID 24332219.Gene therapy for immunodeficiency due to adenosine deaminase deficiency.Bone marrow clonogenic capability, cytokine production, and thymic output in patients with common variable immunodeficiency.Osteopetrosis rescue upon RANKL administration to Rankl(-/-) mice: a new therapy for human RANKL-dependent ARO.Defect of regulatory T cells in patients with Omenn syndrome
P50
Q24310432-A24FDA08-6FF9-4B09-872B-3F30A80824B6Q28302694-FF83A7B7-7749-4EE2-9D25-EFA86CE46124Q33979830-F09FE4B3-F22B-43A8-BC79-8209431C631CQ35568115-AE1F4234-8937-45D3-9DD6-2562D8011DEBQ35568549-6BBE50B9-A1FB-40D1-8564-26DED5F62617Q35837418-1C7A8CDD-4B7D-4BAE-BA28-9356A97ACDBDQ35939764-A4714AD4-4256-4E5F-98E7-B8316C71AF4DQ36165669-05DAA925-F26B-418D-A5F4-0D5185632314Q36298623-4D678582-BC74-4FCF-8E62-DD2118C9058EQ37961515-3F6BEB79-2133-48DD-8D41-8818A767B44AQ38424389-2589B275-9441-483C-B1AA-8D2560586A00Q39598202-F7687150-F139-4D6B-94AD-CEA47DD6A821Q39958215-C6F34DF6-9D50-4D17-ACCF-E5F0C083A1E3Q41137165-1F594B6A-EB7A-4F30-8E87-235DEB92415DQ42249536-D841A659-C908-434F-B276-4BF67BBC689CQ44478345-DE6F0B48-2F99-43B0-9FAB-F3E96988EE76Q45867597-01CA3AFF-0A66-470F-9DD1-23A19B92B359Q45882856-AE77F1E0-9DAF-4606-A473-729277B3D471Q46427526-1A32BADD-03AF-46B2-97F4-A24E76989926Q55056509-819747D6-6794-4E4C-92FC-20197B0B7C9FQ58800410-5C0E8837-0F54-40B5-9378-2E3CB0B6391C
P50
description
researcher, ORCID id # 0000-0002-4115-8109
@en
wetenschapper
@nl
name
Barbara Cassani
@ast
Barbara Cassani
@en
Barbara Cassani
@es
Barbara Cassani
@nl
type
label
Barbara Cassani
@ast
Barbara Cassani
@en
Barbara Cassani
@es
Barbara Cassani
@nl
prefLabel
Barbara Cassani
@ast
Barbara Cassani
@en
Barbara Cassani
@es
Barbara Cassani
@nl
P106
P1153
35261437900
P21
P31
P496
0000-0002-4115-8109